Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sunshine Biopharma Inc SBFM

Healthcare Biotechnology
Sunshine Biopharma, Inc. is a Canada-based pharmaceutical company. The Company offers and researches life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has 27 additional generic prescription drugs. In addition, the Company is engaged in the development of various proprietary drugs, including Adva-27a, K1.1 mRNA and SBFM-PL4. Adva-27a is a... see more

Recent & Breaking News (NDAQ:SBFM)

Sunshine Biopharma Announces Issuance of Notice of Allowance for the Patent Application Covering Adva-27a Anticancer Compound in Canada

Marketwired May 12, 2014

Sunshine Biopharma Secures Funding for Its Adva-27a Anticancer Compound From Dutchess Opportunity Fund II

Marketwired April 29, 2014

Sunshine Biopharma Increases the Effectiveness of Adva-27a Lead Compound 9.5-Fold Against Breast and Pancreatic Cancer in Vitro

Marketwired April 7, 2014

Sunshine Biopharma Increases the Effectiveness of Adva-27a Lead Compound 9.5-Fold Against Breast and Pancreatic Cancer in Vitro

Marketwired April 7, 2014

Management of Sunshine Biopharma Alarmed by the Recent World Health Organization Report That Cancer Is on the Rise

Marketwired March 31, 2014

Management of Sunshine Biopharma Alarmed by the Recent World Health Organization Report That Cancer Is on the Rise

Marketwired March 31, 2014

Sunshine Biopharma Begins Construction of Mouse Xenograft Models for Pancreatic Cancer to Advance Adva-27a as a Treatment for This Deadly Form of Cancer

Marketwired February 14, 2014

Sunshine Biopharma Continues Its Efforts to Re-Domicile in Canada for Business Expansion and Financing Opportunities for Adva-27a Cancer Drug Candidate

Marketwired February 4, 2014

Sunshine Biopharma Targets Pancreatic Cancer as Second Indication for Clinical Trials of Adva-27a Compound

Marketwired January 21, 2014

Sunshine Biopharma to Re-Domicile in Canada for Expansion and Financing Opportunities for Adva-27a Cancer Drug Candidate

Marketwired December 2, 2013

Galectin Shares Rise on IND Filing, is Sunshine Biopharma Next in Line?

Accesswire September 18, 2013

Sunshine Biopharma Parent Company Acquires Garmen Laboratories, a Certified GMP Manufacturing Lab

Marketwired August 26, 2013

Sunshine Biopharma Parent Company Receives $510,000 Research Grant for Adva-27a Cancer Drug Candidate, Brings Total to $1.45 Million

Marketwired August 12, 2013

Sunshine Biopharma's Anticancer Drug Candidate, Adva-27a, Is Unaffected by the Recent Supreme Court Ruling on Patentability of Human Genes

Marketwired June 19, 2013

Sunshine Biopharma's Anticancer Drug Candidate, Adva-27a, Is Unaffected by the Recent Supreme Court Ruling on Patentability of Human Genes

Marketwired June 19, 2013